BioNTECH收购了竞争对手CureVac,价值12.5亿美元,用于推进癌症的MRNA治疗。 BioNTech acquires rival CureVac for $1.25 billion to advance cancer mRNA treatments.

BioNTEch以其与Pfizer的COVID-19疫苗而闻名, 正在以12.5亿美元购买对手CureVac的CureVac, 以利用MRNA技术加强癌症治疗。 BioNTech, known for its COVID-19 vaccine with Pfizer, is acquiring rival CureVac for $1.25 billion to enhance cancer treatments using mRNA technology. 全股交易旨在将两家公司在MRNA设计和制造方面的专门知识结合起来,改善癌症免疫疗法。 The all-stock deal aims to combine both companies' expertise in mRNA design and manufacturing, improving cancer immunotherapy. 该交易经监管批准后,将使CureVac成为BioNTECH的独资子公司。 The transaction, subject to regulatory approval, will make CureVac a wholly-owned subsidiary of BioNTech.